Alumis (ALMS) Reports Q3 Results; Psoriasis NDA on Track for Q4 2026
Alumis reported third-quarter 2026 financial results and business updates. New Phase 3 psoriasis data showed a 54% PASI 100 response rate at 48 weeks; an NDA submission remains on track for Q4 2026.Material DetailsContext by AI AnalystThis is a late-stage clinical and regulatory update for a compan…